Simplified Chinese
A delegation led by the President of the Beijing No. 2 Intermediate People’s Court paid a visit to Minhai.
Release date:
2018-12-27
Author:
Contributed by the General Office
Source:
Abstract
On the morning of December 20, 2018, a delegation of seven, including Lu Guihua, President of the Beijing No. 2 Intermediate People’s Court, paid a visit to the company for research and guidance, accompanied by Zhao Jianxiong, Deputy General Manager of the Biopharmaceutical Base. Zheng Haifa, General Manager of Minhai Bio, along with Wu Chengyu, Assistant to the General Manager, and other company leaders, extended a warm welcome to the visiting delegation from the Beijing No. 2 Intermediate People’s Court.
Zheng Haifa, General Manager of Minhai Biotechnology, briefed the visiting leaders on the company’s overall profile. He provided a detailed overview of the company’s product portfolio, its talent pool, R&D innovation, and quality management, among other areas. The attending leaders unanimously commended Minhai’s development and operational performance. Subsequently, General Manager Zheng discussed the company’s major achievements in recent years, as well as its future development plans and strategic positioning. Dean Lu stated: First, it is essential to earnestly implement the spirit of General Secretary Xi Jinping’s important speech at the symposium on private enterprises, fulfill our duties, and promote the growth of private-sector businesses. Second, we must deepen our understanding of the biopharmaceutical sector and strategic high‑tech industries, strengthen intellectual property protection measures, and provide enterprises with specialized IP‑related support services. Third, we should continuously enhance our capacity for precision‑oriented services, effectively handling corporate litigation, case management, and legal advisory matters, thereby helping enterprises address their practical challenges.
Following the conclusion of the meeting, General Manager Zheng expressed his gratitude to the attending leaders for their support of Minhai Bio’s development. He stated that Minhai Bio will steadfastly uphold the requirements of the Party and the people, rigorously ensure product quality, operate in full compliance with laws and regulations, and make even greater contributions to advancing the nation’s public health and disease prevention efforts.
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account